RARE — Ultragenyx Pharmaceutical Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareAdventurousLarge CapNeutral

Annual cashflow statement for Ultragenyx Pharmaceutical, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2019 December 31st	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	-403	-187	-454	-707	-607
Depreciation
Deferred Taxes
Non-Cash Items	64.7	-62.6	165	249	121
Unusual Items
Purchased R&D
Other Non-Cash Items
Changes in Working Capital	-18.1	105	-63.2	61.9	-13.5
Change in Accounts Receivable
Change in Inventories
Change in Prepaid Expenses
Change in Other Assets
Change in Accrued Expenses
Change in Payable / Accrued Expenses
Change in Other Liabilities
Cash from Operating Activities	-345	-132	-339	-380	-475
Capital Expenditures	-24.8	-43.9	-73.1	-146	-46.8
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items	11.8	-135	-122	-146	215
Acquisition of Business
Sale of Fixed Assets
Sale/Maturity of Investment
Purchase of Investments
Other Investing Cash Flow
Cash from Investing Activities	-13	-179	-195	-292	168
Financing Cash Flow Items	314	-0.236	-0.492	490	-0.028
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	679	600	119	501	388
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	321	290	-417	-172	81.8